Thomas Jefferson Opens New Familial Colorectal Cancer Registry

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 2
Volume 7
Issue 2

PHILADELPHIA-Thomas Jefferson University’s new Familial Colorectal Cancer Registry is collecting information and blood and tissue samples from families with a higher-than-normal risk of colon cancer, to aid researchers looking for genetic markers of the disease and to provide genetic counseling and genetic testing, if appropriate, to participants.

PHILADELPHIA—Thomas Jefferson University’s new Familial Colorectal Cancer Registry is collecting information and blood and tissue samples from families with a higher-than-normal risk of colon cancer, to aid researchers looking for genetic markers of the disease and to provide genetic counseling and genetic testing, if appropriate, to participants.

To date, 35 members of 24 families have been enrolled. Operations director Deborah Rose said she expects to have hundreds of new registry members in the next year.

Typically, a patient is referred to the registry by a physician, family member, or self-referral. To participate, patients may have either a personal or family history of a particular type of inherited colorectal cancer, such as familial adenomatous polyposis or hereditary nonpolyposis colorectal cancer.

Others who are eligible include those who have had colorectal cancer diagnosed before age 30 and patients with a first-degree relative diagnosed with colorectal cancer before age 50.

For more information about the registry and clinical genetic testing, patients and physicians may call 1-800-JEFF-NOW (1-800-533-3669).

Recent Videos
Genetic backgrounds and ancestry may hold clues for better understanding pancreatic cancer, which may subsequently mitigate different disparities.
Factors like genetic mutations and smoking may represent red flags in pancreatic cancer detection, said Jose G. Trevino, II, MD, FACS.
Skin toxicities are common with targeted therapies for GI malignancies but can be remedied by preventative measures and a collaboration with dermatology.
212Pb-DOTAMTATE showed “unexpectedly good” outcomes among those with gastroenteropancreatic neuroendocrine tumors, said Mary Maluccio, MD, MPH, FACS.
Mandating additional immunotherapy infusions may help replenish T cells and enhance tumor penetration for solid tumors, including GI malignancies.
Receiving information regarding tumor-associated antigens or mutational statuses from biopsies may help treatment selection in GI malignancies.
Better defining which patients with GI cancers are preferred candidates for adoptive cellular therapies may help optimize outcomes.
Related Content